Figure 2
Survival of patients with de novo AML and inv(16)/t(16;16) according to CBFB-MYH11 fusion type (non–type A vs type A) and KIT mutation status. (A) OS. (B) EFS. All P-values from pairwise comparisons are adjusted for multiple comparisons.
Survival of patients with de novo AML and inv(16)/t(16;16) according to CBFB-MYH11 fusion type (non–type A vs type A) and KIT mutation status. (A) OS. (B) EFS. All P-values from pairwise comparisons are adjusted for multiple comparisons.
